ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.761,29
0,44%
S&P 500
5.217,24
0,06%
Dow Jones
39.452,59
0,16%
Euro vs US Dollar
1,07634
-0,17%
Bitcoin
61.163,23
-2,99%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) News

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ALNY
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202414h00Business WireAlnylam Issues 2023 Corporate Responsibility ReportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/05/202414h00Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202413h00PR Newswire (Canada)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202413h00PR Newswire (US)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/04/202414h00Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/04/202414h00Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/03/202413h00Business WireAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/03/202412h30Business WireAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202412h50Business WireAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegenNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202423h39Business WireAlnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standardsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202422h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202413h30Business WireAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
04/03/202422h33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/02/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/02/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/02/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/02/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/02/202422h00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/02/202414h30Business WireAlnylam to Webcast Presentations at Upcoming March Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/02/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/02/202422h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/02/202422h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202422h23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202414h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202414h00Business WireAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
10/02/202400h14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ALNY

Kürzlich von Ihnen besucht

TG
RHM
Rheinmetall
DBI
TDXP
Tec DAX
FX
EURGBP
Euro vs Sterling
TG
ALV
Allianz
AMEX
SPY
SPDR S&P 500
TG
MBG
MercedesBenz
USOTC
BNPQY
BNP Paribas (QX)
TG
D7G
Nel ASA
NASDAQ
AMZN
Amazon.com
CCOM
US30
US 30
COIN
ETHUSD
Ethereum
DBI
DAX
DAX
NASDAQ
AAPL
Apple
CCOM
US500
US 500
NYSE
NKE
Nike
CCOM
US100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten